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tive AT2 receptor activation were evaluated in the absence (n=12) and in the presence of
NG-nitro-L-Arginine (L-NA; 3*10-5 M; n=9) or Indomethacin (INDO; 10-3 M; n=7), as well
as, in muscles without endocardial endothelium (EE; n=7). Calculated parameters: active
tension (AT), peak rates of tension rise and decline (dT/dtmax and dT/dtmin, respec-
tively), peak shortening (PS) and peak rate of shortening (dL/dtmax). Results are pre-
sented as mean±SEM in % of baseline (p<0.05). Results: Selective AT2 stimulation
induced a dose-dependent negative inotropic effect, decreasing, at 10-5 M of AT-II,
29.3±7.7% AT, 26.1±7.0% dT/dtmax, 27.9±7.5% dT/dtmin, 30.7±9.3% PS and
22.0±5.7% dL/dtmax. This effect was not influenced by L-NA (10-5 M of AT-II decreased
32.5±10.2% AT, 25.7±7.8% dT/dtmax, 26.7±8.6 dT/dtmin, 16.90±7.1 dL/dtmax) or INDO
(10-5 M of AT-II decreased 34.4±7.1% AT, 27.9±6.1 dT/dtmax, 33.2±7.9 dT/dtmin,
20.2±5.0 dL/dtmax, 36.6±10.2 dL/dtmin, 25.3±7.1 PS), but was completely abolished
after selective removal of the EE. Conclusions: Selective AT2 stimulation induces a neg-
ative inotropic effect, which is modulated by the EE, but not mediated by NO or prostag-
landins. Such findings might help to better understand the therapeutic effects of selective
AT1 antagonists, which are being increasingly used in for treating cardiovascular dis-
eases.
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Background. Inter-individual variability in the response to clopidogrel has recently been
described in patients undergoing percutaneous coronary intervention. A recent ex vivo
study has suggested that: 1) clopidogrel is metabolically activated by cytochrome P450
(CYP)3A4; and 2) clopidogrel may be both an inducer and an inhibitor of CYP3A4. We
hypothesize that the observed variability in the antiplatelet response to clopidogrel may
be in part due to CYP3A4 induction via the nuclear pregane X receptor (PXR) response
element, and/or competitive inhibition of CYP3A4.
Methods. To test whether clopidogrel is capable of CYP3A4 induction in vitro, we used
LS174T tumor cell that express CYP3A4, and is inducible by classical PXR ligands. The
cells were purchased from the American Type Culture Collection (Manassas, VA), plated,
and cultured. Then total RNA was prepared and assayed for CYP3A4 mRNA expression
using real-time polymerase chain reaction analysis in the presence of clopidogrel as
compared to control. To test for CYP3A4 inhibition by clopidogrel, bacterially expressed
human liver CYP3A4 in a reconstituted system was used. Using purified reconstituted
CYP3A4 the clopidogrel-dependent inactivation of the testosterone 6 beta-hydroxylase
activity of CYP3A4 was investigated. The activity of CYP3A4 was measured by high
pressure liquid chromatography. Incremental doses of clopidogrel were added to primary
reaction mixtures containing purified CYP3A4. 
Results. 1 µM and 10 µM clopidogrel induced CYP3A4 mRNA by 3.9 ± 0.2 and 8.7 ± 0.6
fold as compared with control. No mechanism-based or suicide inhibition of CYP3A4 by
clopidogrel was observed (there was no significant loss of CYP3A4 activity following pre-
incubation with clopidogrel and NADPH for 0, 5, 10, and 20 minutes). However, competi-
tive inhibition of CYP3A4 by clopidogrel was observed at concentrations of 2.5 µM and
10 µM of clopidogrel with 61% and 68% of the catalytic activity of CYP3A4 inhibited,
respectively.
Conclusion. Variability in clopidogrel response may be in part explained by the in vitro
findings that clopidogrel is a CYP3A4 inducer and an potent reversible competitive inhibi-
tor of human CYP3A4.
1106-182 Insulin Enhances Vascular Cell Adhesion Molecule -1 
Expression in Human Cultured Endothelial Cells: A Link 
to the Pathogenesis of Accelerated Atherosclerosis in 
Diabetes
Rosalinda Madonna, Assunta Pandolfi, Marika Massaro, Agostino Consoli, Raffaele De 
Caterina, Clinical Sciences and Bioimmages, Chieti, Italy
Hyperinsulinemia is a risk factor for atherosclerosis by mechanisms poorly understood.
We assessed if insulin (I) can increase monocytes - endothelial interactions implicated in
atherosclerosis. Human umbilical vein endothelial cells were incubated with I for 0 - 24
hours ± tumor necrosis factor (TNFα 0.1 ng/mL), lipopolysaccharide (LPS 0.1 ng/mL),
the p38mitogen activated protein(MAP) kinase inhibitor SB203580 (SB 0.1 - 20 µg/mL)
and the phosphatidylinositol (PI)3 - kinase inhibitor wortmannin (WT 10-9 to 10-6mol/L).
Expressions of vascular cell (VCAM -1) or intercellular (ICAM -1) adhesion molecules,
and E -selectin were assessed by enzyme immunoassay (EIA), flow cytometry, immuno-
cytochemistry and northern analysis. U937 cell adhesion to endothelial cells was deter-
mined by a rotational adhesion assay. At pathophysiological concentrations I induced
surface expression of VCAM -1 but not ICAM-1 or E-selectin and potentiated the effects
of TNFα and LPS. I 10 -8 mol/L ± TNF increased U937 cell adhesion by 9.2 and 2.7 fold
respectively, and markedly induced expression of VCAM-1 mRNA. In the absence of any
cytotoxicity WT 10 - 7mol/L potentiated the effect of I alone, while SB 1 µg/mL abolished
this effect. In the Table p< .05 vs unstimulated control *, control with I #, LPS **, TNF ***,
≠ data lacking because of cytotoxicity. In conclusion I promotes VCAM -1 expression by a
p38MAP Kinase pathway amplified by the PI3 -kinase block. This effect may contribute to
atherosclerosis in hyperinsulinemic subjects.
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Background: Adrenomedullin (AM) is a multifonctional regulatory peptide highly
expressed in endothelial cells. AM levels increase in various conditions, including pulmo-
nary hypertension. This study was designed to quantify the in vivo biodistribution and
clearance of AM in rats with special attention to the lungs.
Methods: Plasma kinetics of AM was determined by intra-venous injection of 125I-AM in
rats. The retained radioactivity at equilibrium was determined in the heart, lungs, liver
and kidneys. First pass pulmonary clearance was evaluated by comparing intra-venous
to intra-arterial injections. Arterio-venous plasma and tissue levels of unlabelled AM were
determined in another set of rats.
Results: 125I-AM was rapidly cleared from plasma following a two compartment kinetic
model with a half-life of 12 minutes. The lungs retained the majority of the injected 125I-
AM (figure). There was important first pass pulmonary clearance evidenced by a drop in
extraction from 30.4 1.5% after intra-venous injection to 13.5 0.6% after intra-arterial
injection. Unlabelled AM tissue levels were also much higher in the lungs (figure), how-
ever there was no significant arterio-venous difference of AM in plasma.
Conclusion: The lungs are the major site for AM clearance and production. The lungs
could be a preferential target for this peptide and may modulate its circulating levels
through reduced clearance and/or increased production. 
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Background: Geranylgeranylacetone (GGA) is commonly used as an antiulcer drug. If
GGA affects nitric oxide synthesis in the vascular tissue, it could influence disease pro-
gression in coronary arteries. We investigated the effects of the antiulcer drug GGA on
nitric oxide synthesis in vascular smooth muscle cells.
Methods and Results: Primary cultures of vascular smooth muscle cells were obtained
from the media of thoracic aortae of Sprague Dawley rats. We measured the production
of nitrite, a stable metabolite of nitric oxide, in cultured rat vascular smooth muscle cells
with the Griess reagent. Inducible nitric oxide synthase protein and mRNA expressions
were assayed by Western blotting and reverse transcription-polymerase chain reaction,
respectively. The levels of NF-kappaB proteins in nuclear extracts were analyzed by gel
retardation assay. Heat shock protein 70 (Hsp70), a cytoprotective molecule, was evalu-
ated by Western blotting. Incubation of cultures with interleukin-1beta (10 ng/ml) for 24 h
caused a significant increase in nitrite generation. Interleukin-1beta-induced nitrite pro-
duction by vascular smooth muscle cells was significantly suppressed by GGA in a dose-
dependent manner (10-8-10-4M). GGA-suppressed nitrite production was accompanied
by decreased inducible nitric oxide synthase mRNA and protein accumulations. GGA by
itself did not modulate the basal level of nitrite production. Interleukin-1beta induced NF-
kappaB activation in vascular smooth muscle cells, and the addition of GGA further inhib-
ited this NF-kappaB activation. GGA itself induced Hsp70 protein expression in a dose-
dependent manner.
Conclusions: These findings demonstrated that GGA suppresses nitric oxide synthesis
in cytokine-stimulated cultured vascular smooth muscle cells partially through the sup-
pression of NF-kappaB activation, suggesting that GGA may modulate the pathophysiol-
ogy of cardiovascular diseases including atherosclerosis. In addition, this effect may be
associated with Hsp70 production by GGA.
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